Language Select
Varian Logo

Press Releases

November 20, 2017
At a ribbon-cutting ceremony involving company executives and government officials, Varian Medical Systems (NYSE: VAR) today announced the opening of its new facility in Jundiai, Brazil. One of... Read more
November 16, 2017
Varian Medical Systems (NYSE: VAR) today announced it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market in Japan the Varian Halcyon™ system,... Read more
November 14, 2017
Understanding the important role nurse navigators play in guiding cancer patients through their treatment process, Varian Medical Systems (NYSE: VAR) will be showcasing its new nurse navigation and survivorship solution November 16-19 in Orlando, FL at the AONN+ Navigation & Survivorship Conference, booth #609. This new solution is part of Varian’s 360 Oncology™, a web-based care management platform that integrates relevant health information so patients and their care teams can collaborate on the best care. Read more
November 06, 2017
ALGIERS, Algeria, Nov. 6, 2017 /PRNewswire/ -- Cancer patients in Algeria now have access to modern radiotherapy care with the commencement of treatments at two of six public hospitals currently being equipped by Varian (NYSE: VAR), the world leader in radiotherapy equipment and software. Treatments delivered using linear accelerators including Algeria's first TrueBeam™ systems are being delivered at Sidi-Bel-Abbes and Tlemcen Hospitals in the west of the country. Read more
November 03, 2017
Varian (NYSE: VAR), the world leader in radiotherapy equipment and software, has been selected to equip the greater Copenhagen region’s two radiation oncology departments with modern treatment systems over the next several years. Linear accelerators at the city’s Rigshospitalet and Herlev Hospital oncology departments will be replaced with 15 advanced Varian TrueBeam™ and Halcyon™ treatment machines and two ViewRay MRIdian® MR-Guided Linac systems, which also formed part of the tender. Varian is booking an order for the first four of the TrueBeam™ systems in the current fiscal quarter. Read more
November 01, 2017
Representing the latest step in Varian Medical Systems’ (NYSE: VAR) efforts to expand the availability of high quality cancer care globally, the company announced a 71-year-old male with prostate cancer became the first patient in Australia to be treated on the Halcyon™ system at Radiation Oncology Centres (ROC) in Toowoomba by Brisbane-based Icon Group. Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT), and is well suited to handle the majority of cancer patients, offering advanced treatments for lung, esophagus, brain, head & neck, and many other forms of cancer. Read more
October 30, 2017
Varian Medical Systems (NYSE: VAR) today announced it has named Terilyn Juarez Monroe as Chief People Officer, senior vice-president, Human Resources effective October 30, 2017. Ms. Monroe, 50, is replacing Wendy Scott who is retiring after serving in this same role at Varian for 13 years. Read more
October 25, 2017
Varian Medical Systems (NYSE: VAR) today announced it has been selected to install a ProBeam® four-room proton therapy system in the new Guangzhou Concord Cancer Hospital. Varian will also... Read more
October 25, 2017
Varian Medical Systems (NYSE: VAR) today announced it has been selected by Penn Medicine to install a Varian ProBeam® Compact single-room proton therapy system in a new cancer treatment center.... Read more
October 25, 2017
Fourth Quarter 2017 Summary Oncology gross orders grew 7% Booked 23 Halcyon™ orders, 50 orders since May launch GAAP net earnings per diluted share from continuing operations of $0.89 including... Read more

Corporate Communications Contacts

Corporate Communications Contacts

Corporate Communications Contacts

Mark Plungy
Director, Public Relations
650.424.5630
[email protected]

Mike Bruff
VP, Investor Relations
1 650 424 5163
[email protected]

Neil Madle
Director, Corporate Communications/Investor Relations, Europe
+44 (0)7786 526 068
[email protected]